A study from the Hospital del Mar Research Institute, published in The Journal of Clinical Investigation, indicates that the high expression of the estrogen receptor is the main factor preventing the most common type of breast cancer, luminal breast cancer, from responding to immunotherapy.

The high presence of the estrogen receptor sequesters the LCOR molecule, whose action on tumor cells is necessary to make tumors visible to the immune system. In experimental models, the researchers found that combining immunotherapy with endocrine therapy allows LCOR to function and the immune system to attack the tumor.

At the same time, they have generated a modified version of the LCOR molecule that sensitizes tumors to immunotherapy, including those with hormone receptors. The next goal is to study this molecule combined with immunotherapy in clinical trials.

A team at CABIMER has developed PLAMseq, a technique that for the first time enables the simultaneous identification of chromatin-associated proteins and their precise genomic locations within a single experiment, overcoming limitations of traditional methods like ChIP-seq and mass spectrometry that require complex workflows and specific antibodies. By leveraging rapid TurboID-mediated biotinylation, PLAMseq uncovers previously unknown molecular interactions—such as SETDB1 binding to SUMO-modified histones—and demonstrates strong performance on key genome regulators including CTCF, RNA polymerase II, and modified H1 histones. This integrated proteogenomic approach opens new avenues for investigating epigenetic mechanisms underlying cancer and neurological or developmental disorders, potentially accelerating the discovery of therapeutic targets and biomarkers while positioning Andalusian research groups at the forefront of chromatin biology innovation.

Glycolipid metabolic disorders, linked to cardiovascular diseases and cancer, are a major global health challenge. Current single-disease treatments remain ​unsatisfied in reducing long-term risks. In 2024, Professor Jiao Guo along with global experts launched the "Global Initiative for Glycolipid Metabolic Health" to enhance prevention through scientific research, public education, and integrated management systems.

New research by experts at the University of Sydney shows that breast density notification is leaving some women confused and anxious about their breast health. Breast density notification is being rolled out across Australia, but evidence suggests that women do not feel more informed by it. Between 25 and 40 percent of women have denser breast tissue which can make it harder for cancers to be detected through a mammogram.

Recommendations introduced in Australia and being considered in the UK to tell women if they have dense breasts as part of their screening results may have unintended effects and increase demand on health services, finds a clinical trial designed to assess the real-world impact of notification, published by The BMJ today.